Preclinical data targeting vascular endothelial growth factor in colorectal cancer.
Preclinical data targeting vascular endothelial growth factor in colorectal cancer.
复制标题
DOI：
10.3816/ccc.2004.s.009
复制
发表时间：
2004-10-01
影响因子：
3.4
通讯作者：
Ellis, Lee M
中科院分区：
文献类型：
--
作者：
Ellis, Lee M
血管内皮生长因子（VEGF）是大多数实体恶性肿瘤血管生成的驱动力。这也适用于结直肠癌（CRC），其中原发性癌症中VEGF水平的增加与微血管密度增加和预后不良相关。这些发现导致临床前研究评估抗VEGF治疗在抑制异位和原位CRC生长中的功效。在临床前模型中，许多抑制VEGF活性的方法导致肿瘤生长和血管生成减少。这些研究导致了临床试验，不幸的是，单药抗VEGF治疗对转移性CRC患者相对无效。然而，抗VEGF疗法与化疗的组合已清楚地证明了临床益处。了解VEGF在CRC血管生成中的作用机制以及抗VEGF治疗对肿瘤血管的影响将使肿瘤学家能够优化靶向VEGF及其受体的治疗方案。
Vascular endothelial growth factor (VEGF) is the driving force behind angiogenesis in most solid malignancies. This also holds true for colorectal cancer (CRC), where increased levels of VEGF in primary cancers are associated with increased microvessel density and poor prognosis. These findings have led to preclinical studies evaluating the efficacy of anti-VEGF therapy in inhibiting the growth of CRC in ectopic and orthotopic locations. In preclinical models, numerous approaches to inhibit VEGF activity led to decreased tumor growth and angiogenesis. These studies led to clinical trials in which, unfortunately, single-agent anti-VEGF therapy was relatively ineffective for patients with metastatic CRC. However, combinations of anti-VEGF therapies with chemotherapy have clearly demonstrated clinical benefit. Understanding the mechanisms of the role of VEGF in CRC angiogenesis and the effect of anti-VEGF therapy on the tumor vasculature will allow oncologists to optimize therapeutic regimens targeting VEGF and its receptors.